L-1,2,3,4-四氢异喹啉-3-羧酸盐酸盐 | 77497-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: L-1,2,3,4-四氢异喹啉-3-羧酸盐酸盐
• 中文别名: L-1,2,3,4-四氢异喹啉-3-甲酸盐酸盐；(S)-1,2,3,4-四氢-3-异喹啉羧酸盐酸盐；(S)-(-)-1,2,3,4-四氢异喹啉-3-羧酸盐酸盐
• 英文名称: (3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride
• 英文别名: (3S)-1,2,3,4-terahydroisoquinoline-3-carboxylic acid hydrochloride；L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride；(3S)-1,2,3,4-tetrahydroisoquinole-3-carboxylic acid hydrochloride；(S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride；(S)-3-carboxy-1,2,3,4-tetrahydroisoquinolin-2-ium chloride；(3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;hydrochloride
• CAS: 77497-95-1
• 化学式: C₁₀H₁₁NO₂*ClH
• 分子量: 213.664
• InChiKey: FXHCFPUEIDRTMR-FVGYRXGTSA-N

物化性质

• 熔点：
  >300°C
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.21
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存于阴凉干燥处

SDS

Name:	L-1 2 3 4-Tetrahydroisoquinoline-3-Carboxylic Acid Hydrochloride Material Safety Data Sheet
Synonym:	None
CAS:	77497-95-1

Section 1 - Chemical Product MSDS Name:L-1 2 3 4-Tetrahydroisoquinoline-3-Carboxylic Acid Hydrochloride Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
77497-95-1	L-1,2,3,4-Tetrahydroisoquinoline-3-Car	ca 100	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical aid if irritation develops or persists. Wash clothing before reuse.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 77497-95-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 300 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H11NO2.HCl
Molecular Weight: 213.66

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 77497-95-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
L-1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid Hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 77497-95-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 77497-95-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 77497-95-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  L-1,2,3,4-四氢异喹啉-3-羧酸盐酸盐 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 12.5h， 生成 (S)-tert-butyl 3-(((S)-1-methoxy-1-oxopropan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
  参考文献：
  名称：

  新型1,2,3,4-四氢异喹啉-3-羧酸衍生物作为氨肽酶N / CD13抑制剂的设计，合成及生物学评价

  摘要：

  设计，合成并测定了一系列新颖的1,2,3,4-四氢异喹啉-3-羧酸衍生物对氨基肽酶N（APN / CD13）和MMP-2的活性。结果表明，大多数化合物对APN的抑制活性均高于MMP-2。在该系列中，化合物12h（IC 50  = 6.28±0.11μM）与Bestatin（IC 50  = 5.55± 0.01μM）表现出相似的抑制活性，并且可以用作新型APN抑制剂作为抗癌剂，用于未来的APN抑制剂开发。

  DOI：

  10.1016/j.bmc.2011.08.041
• 作为产物：
  描述：

  聚合甲醛 、 L-苯丙氨酸 在 盐酸 作用下， 以 水 为溶剂， 生成 L-1,2,3,4-四氢异喹啉-3-羧酸盐酸盐
  参考文献：
  名称：

  新型1,2,3,4-四氢异喹啉-3-羧酸衍生物作为氨肽酶N / CD13抑制剂的设计，合成及生物学评价

  摘要：

  设计，合成并测定了一系列新颖的1,2,3,4-四氢异喹啉-3-羧酸衍生物对氨基肽酶N（APN / CD13）和MMP-2的活性。结果表明，大多数化合物对APN的抑制活性均高于MMP-2。在该系列中，化合物12h（IC 50  = 6.28±0.11μM）与Bestatin（IC 50  = 5.55± 0.01μM）表现出相似的抑制活性，并且可以用作新型APN抑制剂作为抗癌剂，用于未来的APN抑制剂开发。

  DOI：

  10.1016/j.bmc.2011.08.041

文献信息

• Total Syntheses of Conformationally Constrained Didemnin B Analogues. Replacements of <i>N</i>,<i>O</i>-Dimethyltyrosine with <scp>l</scp>-1,2,3,4-Tetrahydroisoquinoline and <scp>l</scp>-1,2,3,4-Tetrahydro-7-methoxyisoquinoline
  作者：James E. Tarver、Amy J. Pfizenmayer、Madeleine M. Joullié

  DOI：10.1021/jo0105991

  日期：2001.11.1

  The design and synthesis of two conformationally constrained analogues of didemnin B are described. The [N,O-Me(2)Tyr(5)]residue of didemnin B was replaced with L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) and L-1,2,3,4-tetrahydro-7-methoxyisoquinoline-3-carboxylic acid (MeO-Tic), which mimic the N,O-dimethylated tyrosine while constraining the conformation of the molecule. Preliminary

  描述和设计了两种构型受约束的二氢蝶呤B的类似物。豆双宁B的[N，O-Me（2）Tyr（5）]残基被L-1,2,3,4-四氢异喹啉-3-羧酸（Tic）和L-1,2,3取代， 4-四氢-7-甲氧基异喹啉-3-羧酸（MeO-Tic），可模仿N，O-二甲基化的酪氨酸，同时限制分子的构象。初步结果表明[N，O-Me（2）Tyr（5）]残基的构象与Tic替代所施加的构象非常匹配。
• Dynamic combinatorial chemistry with hydrazones: libraries incorporating heterocyclic and steroidal motifs
  作者：Mark G. Simpson、Michael Pittelkow、Stephen P. Watson、Jeremy K. M. Sanders

  DOI：10.1039/b917146k

  日期：——

  We expand the possibilities in hydrazone based dynamic combinatorial chemistry with a series of new building blocks incorporating heterocyclic motifs. The synthetic procedure allows efficient access to building blocks with the general structure (MeO)2CH-Heterocycle-C(O)NHNH2, originating from heterocycles with an amine and an ester functionality. The equilibrium distribution of macrocyclic N-acyl hydrazones formed upon deprotection of the building blocks with TFA in organic solvents is reported. The mixing behaviour of these heterocycle-based building blocks with our cholate-based building blocks is described, particularly the observation of kinetic intermediates that disappear following ‘proof-reading’.

  我们通过一系列引入杂环基序的新型构建单元，拓展了基于脒的动态组合化学的可能性。合成程序可以高效地获得具有通用结构 (MeO)2CH-杂环-C(O)NHNH2 的构建单元，这些构建单元源自含有胺和酯官能团的杂环化合物。我们还报道了在有机溶剂中用三氟乙酸对这些构建单元进行去保护后形成的宏环 N-酰基脒的平衡分布情况。此外，描述了这些基于杂环的构建单元与我们基于胆酸盐的构建单元的混合行为，特别是观察到在“校对”后消失的动力学中间体。
• Studies on angiotensin-converting enzyme inhibitors. I. Syntheses and angiotensinconverting enzyme inhibitory activity of 2-(3-mercaptopropionyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives.
  作者：KIMIAKI HAYASHI、YASUHIKO OZAKI、KENICHI NUNAMI、TOMOFUMI UCHIDA、JYOJI KATO、KEIZO KINASHI、NAOTO YONEDA

  DOI：10.1248/cpb.31.570

  日期：——

  (3S)-2-[(2S)-3-Mercapto-2-methylpropionyl]-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid [(3S), (2S)-6a] was prepared by the reaction of (3S)-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid tert-butyl ester [(3S)-2a] or benzyl ester [(3S)-2b] with 3-benzoylthio-2-methylpropionyl chloride (3a), followed by fractional crystallization and removal of the protective group. The absolute configuration of (3S), (2S)-6a was confirmed by X-ray diffraction analysis of the thiazepino [4, 3-b] isoquinoline compound (7) derived from 6a. Resolution of 3-benzoylthio-2-methylpropionic acid (8) was completed by using optically active phenylalanine amide as a resolving agent. The other optical isomers of (3S), (2S)-6a were prepared by the reaction of (3S)- or (3R)-2b with optically active 3a. The in vitro ACE inhibitory activity of each isomer of 6a was evaluated. Among them, (3S), (2S)-6a was found to be the most potent inhibitor with an IC50 value of 8.6×10-9M. Compound (3S), (2S)-6a induced a dose-dependent inhibition of the pressor response to angiotensin I after oral administration to normotensive anesthetized rats. Moreover, (3S), (2S)-6a markedly reduced the systolic blood pressure in renal hypertensive rats (RHR) and spontaneously hypertensive rats (SHR). The in vivo ACE inhibitory activity and the hypotensive effects of (3S), (2S)-6a were comparable to those of captopril.

  (3S)-2-[(2S)-3-巯基-2-甲基丙酰基]-1, 2, 3, 4-四氢异喹啉-3-羧酸[(3S), (2S)-6a]是通过(3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸叔丁基酯[(3S)-2a]或苄基酯[(3S)-2b]与3-苯甲酰硫-2-甲基丙酰氯(3a)反应制备而成，随后通过分馏结晶去除保护基团。通过对由6a衍生的噻唑烯[4, 3-b]异喹啉化合物(7)进行X射线衍射分析，确认了(3S), (2S)-6a的绝对构型。使用光学活性的苯丙氨酸酰胺作为分解剂完成了3-苯甲酰硫-2-甲基丙酸(8)的分解。通过(3S)-或(3R)-2b与光学活性3a反应制备了(3S), (2S)-6a的其他光学异构体。评估了每种6a异构体的体外ACE抑制活性。其中，(3S), (2S)-6a被发现是最有效的抑制剂，IC50值为8.6×10^-9M。化合物(3S), (2S)-6a在该显混合型麻醉大鼠口服给药后，诱导了对血管紧张素I的加压反应的剂量依赖性抑制。此外，(3S), (2S)-6a显著降低了肾性高血压大鼠(RHR)和自发性高血压大鼠(SHR)的收缩压。(3S), (2S)-6a的体内ACE抑制活性和降压效果与卡托普利相当。
• Facile Preparation of optically Pure (3S)- and (3R)- 1, 2, 3, 4-Tetrahydroisoquinoline-3-carboxylic Acid
  作者：KIMIAKI HAYASHI、YASUHIKO OZAKI、KENICHI NUNAMI、NAOTO YONEDA

  DOI：10.1248/cpb.31.312

  日期：——

  Optically pure (3S)-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid (1) was easily obtained by fractional crystallization of its benzyl ester (2b) p-toluenesulfonate, which was prepared from partially racemized 1 hydrochloride, followed by catalytic debenzylation. Similarly, (3R)-1 was prepared by the same procedure. The degree of racemization during the Pictet-Spengler reaction using optically active phenylalanine was determined by 1H-nuclear magnetic resonance (1H-NMR) spectroscopy of the corresponding methyl ester (2a), derived from the reaction product (1), in the presence of a chiral shift reagent.

  光学纯的(3S)-1, 2, 3, 4-四氢异喹啉-3-羧酸(1)通过对其苄基酯(2b)的分馏结晶法轻松获得，该苄基酯是由部分消旋的1盐酸盐制备而成，随后经过催化去苄基化。同样，(3R)-1也是通过相同的程序制备的。在使用光学活性的苯丙氨酸进行Pictet-Spengler反应时，通过在存在手性位移试剂的情况下，对反应产物(1)所得到的相应甲基酯(2a)进行1H核磁共振(1H-NMR)光谱分析，确定了消旋化的程度。
• New approaches towards the synthesis of 1,2,3,4-tetrahydro isoquinoline-3-phosphonic acid (TicP)
  作者：José Luis Viveros-Ceballos、Lizeth A. Matías-Valdez、Francisco J. Sayago、Carlos Cativiela、Mario Ordóñez

  DOI：10.1007/s00726-021-02962-4

  日期：2021.3

  new strategies for the efficient synthesis of racemic 1,2,3,4-tetrahydroisoquinoline-3-phosphonic acid (TicP) (±)-2 have been developed. The first strategy involves the electron-transfer reduction of the easily obtained α,β-dehydro phosphonophenylalanine followed by a Pictet–Spengler cyclization. The second strategy involves a radical decarboxylation–phosphorylation reaction on 1,2,3,4-tetrahydroi

  已开发出两种有效合成外消旋 1,2,3,4-四氢异喹啉-3-膦酸 (Tic P ) (±)- 2 的新策略。第一种策略涉及容易获得的 α,β-脱氢膦酰基苯丙氨酸的电子转移还原，然后是 Pictet-Spengler 环化。第二种策略涉及 1,2,3,4-四氢异喹啉-3-羧酸 (Tic) 的自由基脱羧-磷酸化反应。在这两种策略中，高度亲电的N-酰基胺离子作为关键中间体形成，使用温和的反应条件和容易获得的起始材料以良好的收率获得目标化合物，补充现有方法并有助于 (±) - 2 以供进一步研究。